Skip to main content
Caplight Logo









Pharmasum Therapeutics

Pharmasum Therapeutics

Private
OsloHealthcare & Life Scienceshttps://investorpharmasum.com/

Last Round

Crowdfunding

Jun 28, 2023

Total Funding Raised

$3.27M

Company Overview

Pharmasum Therapeutics is a biotechnology company focused on the discovery and development of novel human medicines for the treatment of neurological, autoimmune, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

drug discoverybiotechsmall-molecule drugsdrug developmentbiopharmaprotein kinase inhibitorsDYRK1A inhibitorkinase inhibitorneurodegenerative diseasealzheimer's researchdrug licensingpharma pipelinelead optimizationpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pharmasum Therapeutics Comparables

Compare Pharmasum Therapeutics with similar companies based on industry and business-model similarity.

Pharmasum Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Perha Pharmaceuticals
87%
T3D Therapeutics, Inc.
77%
AgeneBio, Inc.
72%

Pharmasum Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingJun 28, 2023
GrantFeb 5, 2015

Pharmasum Therapeutics Investors

Notable investors and investment history

Pharmasum Therapeutics investors
InvestorRounds
Innovasjon NorgeGrant
FolkeinvestCrowdfunding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 27, 2024

    Grew 200% QoQ from 2 to 6 employees.

  • Sep 13, 2024

    Grew 500% QoQ from 1 to 6 employees.

Pharmasum Therapeutics Filings

Explore SEC and related filing metadata, where available.

Pharmasum Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pharmasum Therapeutics's valuation, stock price, and market status.

Is Pharmasum Therapeutics a public or private company?

Pharmasum Therapeutics is a private company.

What is the current stock price of Pharmasum Therapeutics?

Pharmasum Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Pharmasum Therapeutics worth (valuation)?

Valuation information for Pharmasum Therapeutics is not publicly available.

Can I buy Pharmasum Therapeutics stock?

Pharmasum Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Pharmasum Therapeutics's last funding round?

Pharmasum Therapeutics's most recent funding round was Crowdfunding on June 28, 2023.

Who are the main investors in Pharmasum Therapeutics?

Key investors in Pharmasum Therapeutics include Innovasjon Norge, Folkeinvest.

Will Pharmasum Therapeutics IPO soon?

No public IPO plans have been announced for Pharmasum Therapeutics.

How can I track Pharmasum Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pharmasum Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOslo
Employee Range7
Year Founded2014
Last FundingJun 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?